Table 5.
Serum concentration -median (IQR)- of validated proteins in SSc patients, according to the cutaneous subset.
| dcSSc | lcSSc | sine SSc | lcSSc + sine SSc | |
|---|---|---|---|---|
| Aldolase A | 85.5 (80.5-104)° | 83.7 (74.0-95.5)° | 123 (116-148)^° | 92.5 (74.7-102.4) |
| Ang2 | 1.58 (0.80-2.72) | 1.17 (0.66-2.39) | 0.58 (0.37-1.65) | 1.08 (0.58-2.12) |
| BAFFR | 1.67 (0.80-3.20) | 1.01 (0.60-1.84) | 0.60 (0.34-1.62) | 1.01 (0.56-1.84) |
| Calgranulin B | 65.7 (62.2-81.8)*° | 25.3 (16.5-33.1)° | 49.0 (34.5-64.7)° | 25.6 (16.6-40.8)* |
| Calpain | 13.6 (12.7-14.7) | 13.4 (12.4-14.0) | 12.8 (12.5-14.4) | 13.4 (12.4-14.0) |
| CD177 | 7.28 (4.97-14.7) | 12.2 (8.79-19.9) | 8.97 (3.68-10.9) | 11.3 (8.17-19.9) |
| Eotaxin | 1.35 (0.83-1.75) | 0.95 (0.65-1.21) | 0.55 (0.40-0.80) | 0.94 (0.49-1.18) |
| Fractalkine | 2.90 (1.07-3.32) | 2.00 (1.35-4.01) | 3.24 (2.89-4.72) | 2.78 (1.39-4.08) |
| IL-22BP | 24.9 (16.8-86.4) | 27.8 (15.3-52.7) | 23.6 (15.7-36.9) | 26.6 (15.8-50.9) |
| Kininogen | 505 (286-707) | 591 (390-717) | 384 (352-416) | 564 (371-699) |
| Leptin | 1.74 (0.79-3.00) | 2.87 (0.77-4.92) | 0.18 (0-1.21)^ | 2.09 (0.48-4.70) |
| MMP-12 | 0.07 (0.03-0.20) | 0.13 (0.09-0.18) | 0.05 (0.03-0.09) | 0.11 (0.08-0.16) |
| TPSB2 | 23.5 (0-72.3) | 71.7 (30.7-162) | 64.6 (33.5-103) | 71.7 (31.3-151) |
dcSSc, diffuse cutaneous subset of SSc; lcSSc, limited cutaneous subset of SSc; sine SSc, SSc sine scleroderma.
*p < 0.05 comparing dcSSc vs. lcSSc and SSc sine scleroderma.
^p < 0.05 comparing SSc sine scleroderma vs. dcSSc and lcSSc.
°p < 0.05 comparing dcSSc vs. lcSSc vs. SSc sine scleroderma (three-group Kruskal-Wallis).